Janus Kinase Inhibitor

ApprovedSmall molecule

PPeking Union Medical College Hospital

Janus Kinase Inhibitor is one of 116 small molecule programs targeting Blau syndrome. It is currently in Approved.

Indications

Total Trials

Active Trials

115

Competitors

Pipeline

Status by Indication[3][1]

Indication

Blau SyndromeActive, not recruiting

Bullous PemphigoidActive, not recruiting

Rheumatoid ArthritisActive, not recruiting

Ulcerative ColitisActive, not recruiting

COVID-19Active, not recruiting

Blau SyndromeApproved

Active, not recruiting

Bullous PemphigoidPreclinical

Active, not recruiting

Rheumatoid ArthritisPhase 3

Active, not recruiting

Ulcerative ColitisPreclinical

Active, not recruiting

COVID-19Phase 2/Phase 3

Active, not recruiting

Competition

Competitive Landscape

1931 competitors in COVID-19

#DrugCompanyPhaseTrials

Janus Kinase Inhibitor

PPeking Union Medical College Hospital

Approved

1 2

Proventil

Mylan Pharmaceuticals Inc

Preclinical

1 3

Piperacillin/tazobactam

Pfizer

Preclinical

1 4

Aprotinin

Bayer

Preclinical

1 5

Antithrombin-III

Octapharma

Preclinical

1 6

Interferon-Gamma

SSPP Pharmaclon Ltd.

Preclinical

1 7

Biological Collection

AAssistance Publique - Hôpitaux de Paris

Preclinical

1 8

Antihypertensive Agents

NNational Heart, Lung, and Blood Institute (NHLBI)

Preclinical

1 9

Tpa

UUniversity of Florida

Preclinical

1 10

Pfizer-COVID-19 Vaccine

Moderna

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Rheumatoid Arthritis1 trial

Efficacy and Safety of Abatacept Combined With JAK Inhibitor for Refractory Rheumatoid Arthritis

Unknown status·ZZhejiang Provincial People's Hospital·Phase 3·NCT05451615·90 enrolled

Blau syndrome1 trial

Efficacy and Safety of Tofacitinib in Refractory Blau Syndrome

Enrolling by invitation·PPeking Union Medical College Hospital·Phase 4·NCT06660329·30 enrolled

Bullous Pemphigoid1 trial

JAK Inhibitors' Efficacy in Bullous Pemphigoid

Completed·CChao Ji··NCT06561256·120 enrolled

Ulcerative Colitis1 trial

Identification of Biomarkers of Janus Kinase Inhibitor Therapy in Patients With Ulcerative Colitis

Terminated·AAlimentiv Inc.··NCT04576000·3 enrolled

COVID-191 trial

Ruxolitinib for Acute Respiratory Disorder Syndrome Due to COVID-19

Terminated·VVanderson Geraldo Rocha·Phase 2/3·NCT04477993·5 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Janus Kinase Inhibitor. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Janus Kinase Inhibitor compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Janus Kinase Inhibitor. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Peking Union Medical College Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: PPeking Union Medical College Hospital

Janus Kinase Inhibitor

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Rheumatoid Arthritis1 trial

Blau syndrome1 trial

Bullous Pemphigoid1 trial

Ulcerative Colitis1 trial

COVID-191 trial

References

Drug Info

Quick Facts

Related News